Heart failure & cardiomyopathiesRandomised controlled trial
Landiolol for rate control in decompensated heart failure due to atrial fibrillation: the LARISA trial
- randomized
- protocolized
Authors' conclusion
In AHF with reduced LVEF, protocolized landiolol-based intensive rate control provides faster and safe HR reduction with early symptomatic benefit compared with standard therapy. Pre-registered Clinical Trial Number: ClinicalTrials.org: NCT04694092.
Study context
- Population
- Patients with acute heart failure (AHF) due to atrial fibrillation (AF) [heart rate (HR) > 130/min, left ventricular ejection fraction (LVEF) <40%]randomized
- Participants
- Forty patients
- Comparison
- Intensive rate control (IRC) with landiolol plus digoxin vs standard rate control therapy
- Primary endpoint
- Sustained HR reduction >20% or <115/min
- Follow-up
- 2 h
Primary result
As reported in the abstract
Further findings
Time to HR control
HR decrease · 2 h
- Time to HR control: P = 0.016
- HR decrease: P = 0.045
Dyspnoea relief and lung decongestion
- Greater dyspnoea relief and lung decongestion with IRC
Outcomes at 24 h
- Outcomes between the groups were similar
Original publication
Landiolol for rate control in decompensated heart failure due to atrial fibrillation: the LARISA trial. Eur Heart J Acute Cardiovasc Care. Published 27 February 2026. doi:10.1093/ehjacc/zuag027
Summarised from the published abstract; every number is checked against it